Haines MS et al
Pertenece a una clase de medicamentos conocidos como Receptor de GLP-1 agonistas, que ayudan a regular el apetito, los niveles de azcar en la sangre , y respuesta a la insulina
These completely separate metabolic pathways mean neither medication alters the blood levels of the other
GLP-1R market: A two-horse race, says GlobalData As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion by 2030 The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their ability to effectively treat metabolic-related disorders such as obesity and type 2 diabetes
While regulatory concerns and health safety considerations may impact market expansion, ongoing research and development into safer formulations could further boost consumer confidence
In 2023, an exciting development occurred as the NGP Verified item Lake States Type E produced in Europe was complemented by its corresponding NGP verified item produced in Rhinelander, Wisconsin and named Lake States Type N
